MAGNITUDE Patient Summary
The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.
AM I ELIGIBLE?
You may be eligible to participate in this study if you:
Before you participate in this study, a detailed description of the study, as well as possible risks and benefits, will be provided in writing in an “informed consent document” and discussed with you. You will be asked to review and sign the informed consent document prior to participating. Your medical history will be reviewed, and you will be given a study required medical exam and have study required laboratory tests such as blood draws.
STUDY DESIGNThe purpose of the study is to compare a combination of the investigational medicine to standard treatment versus a combination of placebo and standard treatment for the treatment of patients with metastatic prostate cancer. A placebo is an inactive treatment, sometimes referred to as a “sugar pill,” that will be provided as capsules and will match the investigational medicine in size, weight, color, shape, and taste.
Once enrolled in the study, feel free to discuss your investigational medication with the study doctor or research staff at any time during the study. Information collected during a clinical research study may or may not ultimately lead to the investigational medicine(s) being approved by regulatory health authorities. Your participation in the study is voluntary and you can leave the study at any time. Compensation for time and travel may be available.
To learn more about this study and to find out if you may be eligible and if the study is being conducted at a site near you, please visit:
Clinical Trials.gov Information
Contacts and Trial Site Locations
Organization: Janssen Research & Development, LLC
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.